![]() |
市場調查報告書
商品編碼
1471139
幹細胞市場:按類型、來源、應用、最終用戶分類 - 2024-2030 年全球預測Stem Cells Market by Type (Adult Stem Cell, Human Embryonic Stem Cell, Induced Pluripotent Stem Cell), Source (Allogenic, Autologous), Application, End-user - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年幹細胞市場規模為136.6億美元,預計2024年將達到150.5億美元,2030年將達到279.9億美元,複合年成長率為10.79%。
幹細胞市場由用於研究、開發和醫療應用的各種產品和服務組成。這包括銷售幹細胞株、用於操縱和分析幹細胞的設備,以及與幹細胞庫相關的服務以及在各種疾病治療中的應用。幹細胞在再生醫學領域有著廣泛的應用,包括帕金森氏症、阿茲海默症、糖尿病和心臟病。它對於各種癌症治療方法的開發也至關重要。最終用戶包括直接對患者進行幹細胞治療的研究機構、生技公司、製藥公司、醫院和診所。幹細胞市場的成長是由幹細胞研究資金的增加、再生治療需求的增加以及使幹細胞治療更容易獲得和有效的技術進步所推動的。此外,全球慢性病的盛行率不斷上升,需要開發創新的治療方法,並推動對幹細胞領域的進一步投資。然而,胚胎幹細胞研究存在倫理問題,包括幹細胞治療的高成本、需要訓練有素的人員、幹細胞治療的免疫排斥的可能性以及製造幹細胞產品的複雜性,這些都阻礙了胚胎幹細胞研究的發展。治療的普及。同時,幹細胞市場最大的商機在於新藥發現平台的開發、個人化醫療的應用以及幹細胞儲存和分析的技術創新。擴大誘導性多功能幹細胞(iPS 細胞) 的治療應用以及利用幹細胞進行組織和器官再生的 3D 生物列印技術的進步也是值得探索的領域。
主要市場統計 | |
---|---|
基準年[2023] | 136.6億美元 |
預測年份 [2024] | 150.5億美元 |
預測年份 [2030] | 279.9億美元 |
複合年成長率(%) | 10.79% |
由於道德和監管障礙較低,成體幹細胞的使用正在增加
成體幹細胞是胚胎發育後存在於全身的未分化細胞。存在於骨髓、血液、腦部和肌肉組織。成體幹細胞是多功能的,可以發展成多種細胞類型,但與多功能能幹細胞相比這是有限的。成體幹細胞主要透過骨髓移植用於治療多種疾病,包括血液疾病。人類胚胎幹細胞 (hESC) 源自於胚囊的內細胞群,囊胚胚胎著床前胚胎的早期階段。這些多功能細胞可以分化成體內的所有細胞類型,提供廣泛的治療可能性。 hESC 具有分化成任何細胞類型的能力,對於了解人類早期發育、遺傳疾病和藥物篩檢具有不可估量的價值。誘導性多功能幹細胞(iPSC)是一種透過引入特定基因從非多功能細胞(通常是成體細胞)合成衍生的幹細胞。 iPSC 在再生醫學領域前景廣闊,因為它們可以在體內生成任何類型的細胞,而不會出現與 hESC 相關的倫理問題。幹細胞市場多種多樣,每種幹細胞都有獨特的優勢,但也面臨不同的挑戰。成體幹細胞廣泛存在,倫理和監管障礙較低,但其分化潛力有限。人類胚胎幹細胞由於其多功能而具有巨大的治療潛力,但倫理爭論和限制性法律阻止其在許多國家的使用。誘導性多功能幹細胞(幹細胞)雖然是一項新技術,可提供量身定做的治療方法並避免倫理限制,但需要進行大量研究以確保臨床應用的安全性和有效性。
擴大幹細胞在發展應用診斷模型的應用
診斷領域是幹細胞應用極為重要的領域,對於各種疾病的早期發現和監測非常有用。幹細胞正在幫助開發模擬人類疾病的診斷模型,使研究人員能夠了解病理學並測試新的診斷方法。對早期準確疾病診斷的需求不斷增加,推動了對涉及幹細胞的創新診斷解決方案的需求。幹細胞在藥物發現和藥物開發中發揮創新作用。提供人類特異性模型有可能透過減少對動物實驗的依賴並提高預測藥物反應的準確性來徹底改變藥物篩檢過程。製藥業降低成本和增加有效藥物管道的壓力正在推動幹細胞技術在藥物發現和藥物開發中的採用。再生醫學是幹細胞最有前景的應用領域,具有治癒受損組織和器官的潛力,並為以前無法治癒的疾病提供解決方案。再生醫學領域正在利用幹細胞的獨特能力來突破傳統醫學的界限。對再生醫學的需求是由患者主導的,通常針對治療選擇有限的情況,例如脊髓損傷、燒燙傷和心臟疾病,因此迫切需要新的治療方法。
區域洞察
在美國,幹細胞市場是由高水準的研究投資和強大的專利環境所推動的。憑藉強大的法規結構,研究機構和公司處於幹細胞研究和臨床試驗的前沿。加拿大消費者越來越了解幹細胞治療的潛在好處,從而推動了需求的成長。然而,該市場的特點是對監管核准和專利申請採取謹慎態度。南美幹細胞市場仍在發展中,但由於醫療基礎設施投資增加和醫療旅遊業興起,預計將出現成長。由於成熟的製藥業和有利的政府政策,歐洲是幹細胞的重要市場。歐盟 (EU) 有關幹細胞研究的嚴格法規確保道德實踐和高品質標準,資金和合作研究機會正在促進市場成長。瑞士、德國、英國和法國等國家對幹細胞研究有著非常支持的氛圍,擁有眾多的跨國合作關係和大量資金。中東地區對幹細胞研究的興趣和投資正在成長,特別是在沙烏地阿拉伯和以色列等以醫療創新而聞名的國家。非洲的幹細胞市場仍在發展但前景廣闊,而南非則處於領先地位。在人口老化加劇、醫療成本上升以及政府支持政策的背景下,亞太地區幹細胞市場正在快速開拓。由於國家主導的措施和對生物技術的大量投資,中國的幹細胞市場正在迅速擴大。日本以其前瞻性的監管政策而聞名,尤其是再生醫學的快速核准制度。日本消費者對幹細胞療法的高度信任很大程度上歸功於政府的廣泛支持和有利於技術進步的文化。印度幹細胞市場正在興起,研究舉措數量不斷增加,消費者興趣不斷成長。
FPNV定位矩陣
FPNV定位矩陣對於評估幹細胞市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對幹細胞市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,以獲得市場競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4.競爭評估及資訊:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行綜合評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1. 幹細胞市場的市場規模與預測是多少?
2.幹細胞市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些?
3. 幹細胞市場的技術趨勢和法規結構是什麼?
4.幹細胞市場主要廠商的市場佔有率是多少?
5. 進入幹細胞市場的合適型態和策略性手段是什麼?
[187 Pages Report] The Stem Cells Market size was estimated at USD 13.66 billion in 2023 and expected to reach USD 15.05 billion in 2024, at a CAGR 10.79% to reach USD 27.99 billion by 2030.
The stem cell market comprises various products and services used for the research, development, and application of stem cells in medical therapies. It includes the sale of stem cell lines, instruments used in the manipulation and analysis of stem cells, and services related to stem cell banking and therapeutic applications across various disease treatments. Stem cells find extensive applications in regenerative medicine for diseases such as Parkinson's, Alzheimer's, diabetes, and heart disease. They also are vital in developing various cancer treatments. End-users include research institutes, biotech companies, pharmaceutical corporations, hospitals, and clinics applying stem cell therapies directly to patients. Growth in the stem cell market is primarily driven by the increased funding for stem cell research, rising demand for regenerative treatment options, and advancements in technology that make stem cell therapies more accessible and effective. Additionally, the growing incidence rates of chronic diseases worldwide necessitate the development of innovative treatment approaches, fostering further investment in the stem cell sector. However, the adoption of stem cells is hindered by ethical issues covering embryonic stem cell research, the high costs of stem cell therapies, the need for adequately trained personnel, the potential immune rejection of stem cell therapies, and the complexity of manufacturing stem cell products. On the other hand, the most significant opportunities in the stem cell market lie in the development of new drug discovery platforms, applications in personalized medicine, and technological innovations in stem cell preservation and analysis. Expansion of the therapeutic applications of induced pluripotent stem cells (iPSCs) and advancements in 3D bioprinting utilizing stem cells for tissue and organ regeneration are other areas for exploration.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 13.66 billion |
Estimated Year [2024] | USD 15.05 billion |
Forecast Year [2030] | USD 27.99 billion |
CAGR (%) | 10.79% |
Type: Increasing usage of adult stem cells due to its fewer ethical and regulatory hurdles
Adult stem cells are undifferentiated cells located throughout the body after embryonic development. They can be discovered in bone marrow, blood, brain, and muscle tissues. Adult stem cells are multipotent, meaning they can develop into more than one cell type but are limited compared to pluripotent stem cells. Adult stem cells are primarily used to treat various diseases, including hematological conditions, through bone marrow transplants. Human embryonic stem cells (hESCs) are sourced from the internal cell group of a blastocyst, an early-stage pre-implantation embryo. These pluripotent cells can develop into any cell type of the body, offering broad therapeutic potential. With their ability to differentiate into any cell type, hESCs are immensely valuable for understanding early human development, genetic diseases, and drug screening. Induced pluripotent stem cells (iPSCs) are a kind of stem cell synthetically derived from non-pluripotent cells, typically adult somatic cells, by introducing certain genes. iPSCs hold promise in regenerative medicine because they can give rise to every cell type in the body without the ethical issues associated with hESCs. iPSCs are particularly promising for personalized medicine, as they can be derived from a patient's cells, reducing the risk of rejection. The stem cell market is diverse, with each type of stem cell offering unique benefits and facing distinct challenges. Adult stem cells are widely used and have fewer ethical and regulatory hurdles but offer limited differentiation potential. Human embryonic stem cells show vast therapeutic potential given their pluripotency, but their use is impaired by considerable ethical debates and restrictive legislation in many countries. Induced pluripotent stem cells, although a newer technology, provide tailored treatments and avoid ethical constraints but require significant research and development to ensure their safety and efficacy in clinical applications.
Application: Expanding the application of stem cells in developing diagnostic models
The diagnostic segment is a crucial area within stem cell applications, facilitating the early detection and monitoring of various diseases. Stem cells are instrumental in developing diagnostic models that mimic human diseases, enabling researchers to understand pathology and test new diagnostic methods. There's a growing need for accurate disease diagnosis early, subsequently increasing the demand for innovative diagnostic solutions involving stem cells. Stem cells play a transformative role in drug discovery and development. They have the potential to revolutionize the drug screening process by providing human-specific models, which can lower the dependency on animal testing and improve the predictive accuracy of drug responses. The pharmaceutical industry's pressure to reduce costs and increase the pipeline of effective drugs is a driving force behind the adoption of stem cell technologies in this drug discovery and development. Regenerative medicine is the most promising application of stem cells, potentially healing damaged tissues and organs and offering solutions for previously untreatable conditions. The regenerative medicine sector is pushing the boundaries of traditional medical treatments, harnessing the unique capabilities of stem cells. The demand in regenerative medicine is patient-driven, often for conditions with limited treatment options, such as spinal cord injuries, burns, and heart diseases, creating a significant need for novel therapeutic approaches.
Regional Insights
In the United States, the stem cell market is driven by high levels of investment in research and a strong patent landscape. With a robust regulatory framework, institutions and companies are at the forefront of stem cell research and clinical trials. Canadian consumers are becoming increasingly knowledgeable about the potential benefits of stem cell therapies, prompting a rise in demand. However, the market is also characterized by a cautious approach to regulatory approvals and patenting. The stem cell market in South America is still in the developmental phase but is expected to grow due to growing investment in healthcare infrastructure and rising medical tourism. Europe is a significant market for stem cells, with the presence of a well-established pharmaceutical industry and favorable government policies. The European Union's strict regulations on stem cell research ensure ethical practices and high-quality standards, while funding and collaboration opportunities contribute to the market growth. Countries such as Switzerland, Germany, the UK, and France showcase a highly collaborative atmosphere for stem cell research, with numerous cross-border partnerships and substantial funding. The Middle East has shown increasing interest in stem cell research and investment, particularly in countries, including Saudi Arabia, or Israel, which is known for its innovation in medical technology. Africa has a nascent but promising stem cell market, with South Africa at the forefront regarding research efforts and regulatory structure. The APAC region is witnessing rapid development in the stem cell market due to the increasing geriatric population, rising healthcare expenditure, and supportive government policies. China's stem cell market is expanding rapidly due to state-led initiatives and significant investment in biotechnology. Japan is known for its forward-looking regulatory policies, especially the fast-track approval system for regenerative medicine. Japanese consumers highly trust stem cell treatments, largely due to extensive government backing and a culture that favors technological advancement. India's stem cell market is emerging, with an increasing number of research initiatives and growing consumer interest.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Stem Cells Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Stem Cells Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Stem Cells Market, highlighting leading vendors and their innovative profiles. These include Advanced Cell Technology, Inc., AlloSource, Inc., Anterogen Co., Ltd., Athersys Inc., Becton, Dickinson and Company, Bioheart Inc., Biorestorative Therapies Inc., BioTime, Inc., BrainStorm Cell Therapeutics Inc., Celgene Corporation, Cellartis AB, CellGenix GmbH, Cellular Engineering Technologies Inc., Gamida Cell Ltd, GenScript Biotech Corporation, Gilead Sciences, Inc., Holostem Terapie Avanzate Srl by Fondazione Enea Tech e Biomedical,, JCR Pharmaceuticals Co., Ltd., Lonza Group Ltd, Novartis AG, NuVasive Inc., Pluristyx, Inc., RTI Surgical, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Stem Cells Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Stem Cells Market?
3. What are the technology trends and regulatory frameworks in the Stem Cells Market?
4. What is the market share of the leading vendors in the Stem Cells Market?
5. Which modes and strategic moves are suitable for entering the Stem Cells Market?